Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Effectiveness of Apixaban Compared to Warfarin in NVAF Patients at Higher Risk of Bleeding.

NCT05471505 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05471505
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05471505 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Effectiveness of Apixaban Compared to Warfarin in NVAF Patients at Higher Risk of Bleeding.
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
August 25, 2022
Completion date
September 27, 2022
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-valvular atrial fibrillation